

IVD



Hain Lifescience - a Bruker Company

FluoroType[®] MTBDR VER 2.0

● Tomorrow's TB diagnostics today

Single-tube high-multiplex PCR and subsequent fluorescence-based detection of *M. tuberculosis* complex and its resistance against rifampicin and isoniazid from sputum specimens or cultivated samples.

Your benefits of using FluoroType[®] MTBDR

- **Novel technology:** The test system is based on the innovative **LiquidArray** technology. It thus enables reliable MDR-TB diagnostics within 2.5 hours only.
- **True MDR-TB testing:** Resistances to both first-line drugs, rifampicin and isoniazid, are reliably identified, as well as mono-resistances.
- **Reliable results:** The assays can detect silent mutations within the *rpoB* gene and therefore allows confidence when testing for resistance.
- **Flexible and intelligent software:** The user-friendly and machine learning, specific **FluoroSoftware** does the evaluation and interpretation. A high number of resistance-mediating mutations is specified within the result report. In addition, rare or so far unknown mutations in the target genes are also shown.
- **Fully automated solution possible:** Amplification and detection run fully automated in a closed system, the **FluoroCycler[®] XT**. Nucleic acid extraction can be automated by using the **GenoXtract[®] 96*** device.

Facts


Multidrug-resistant tuberculosis (MDR-TB) is an alarming and ongoing global issue which requires fast intervention in order to prevent further spread of the disease. More and more frequently, mono-resistant strains are found. Thus, utilising a test system that provides rapid and reliable results for the two most important first-line drugs, rifampicin and isoniazid, provides clinicians with greater information. In consequence, it allows them to make an informed decision on how to treat their patients with the most appropriate therapy. Our automated diagnostics offer convenience and standardization to laboratories allowing them to report high quality and reproducible results to their clinicians.



FluoroType® MTBDR is based on the innovative **LiquidArray** technology.

Within one reaction the test allows for the detection of *M. tuberculosis* complex and identification of mutations within the *rpoB*, *inhA* and *katG* genes. By using the **LiquidArray** technology, also rare or so far unknown mutations in the target genes can be reliably detected. Additionally, it is possible to enter information on novel mutations into the machine learning software in order to ensure their specification in the future.

DNA extraction can be performed manually using **FluoroLyse** or fully automated with the **GenoXtract® 96***. Using this instrument, a completely automated processing is possible: After DNA isolation and PCR set-up, the plate



can be directly placed into the **FluoroCycler® XT** for amplification and detection. An Internal Control documents the correct test procedure and valid results.

The results are evaluated and displayed in the **FluoroCycler® XT Report**. Fully automated, fast and reliable results at one glance are therefore guaranteed.

Thus, **FluoroType® MTBDR** is a valuable tool in the fight against MDR-TB!

** Coming soon. This product may have become available in the meantime. Please contact us for further information. The information in this flyer is correct as of March 2019.*

Please contact your local sales representative for availability of these IVD products in your country.

● Hain Lifescience GmbH

Hardwiesenstraße 1
72147 Nehren - Germany
Phone +49 (0) 7473-9451-0
Fax +49 (0) 7473-9451-31



info@hain-lifescience.de - www.hain-lifescience.de